Skip to content

Study · Not a test of the peptide alone · 2004

3 results

A comparative analysis of RNA targeting strategies in the thymosin beta 4 gene.

Gibbons DL, Shashikant C, Hayday AC

Journal of molecular biology1 Sept 2004Cited by 9 (Europe PMC)

PMID15351635 (opens in a new tab)DOI10.1016/j.jmb.2004.07.081 (opens in a new tab)PepBankPUB-15351635
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In cells, both shRNAi and EGS targeted the thymosin beta4 gene, and shRNAi reduced RNA by about 90%, more than EGS.

    In plain wordsIn cells, two RNA-targeting methods both lowered thymosin beta4 RNA, and the shRNAi method lowered it more, by about 90%.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseTbeta4 RNA reduction with shRNAi versus EGS
    Study

    n: not reported in source

    Comparator
    EGS-mediated RNase P cleavage
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    RNA reduction
    ≈ 90%
    shRNAi

    Source sentences

    Summary
    The data demonstrate that shRNAi and EGS can both target the Tbeta4 gene, but that the extent of RNA reduction with shRNAi ( approximately 90%) is greater.
    1 context sentence
    Summary · context
    Therefore, we have used the Tbeta4 gene to compare alternative strategies for RNA targeting, namely short hairpin (sh) RNAi versus external guide sequence (EGS)-mediated RNase P cleavage.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    In cells, RNAi showed varying efficacy against two overlapping Tbeta4 RNAs and was largely but not completely splice form-specific.

    In plain wordsIn cells, RNAi against thymosin beta4 worked differently on two overlapping RNAs and was mostly, but not fully, specific to one splice form.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    MixedSplice form specificity of RNAi targeting
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    RNAi targeting shows varying efficacy against two overlapping RNAs, is largely but not completely splice form-specific, and preferentially, but not exclusively, targets a perfect-sequence match.
    1 context sentence
    Summary · context
    Therefore, we have used the Tbeta4 gene to compare alternative strategies for RNA targeting, namely short hairpin (sh) RNAi versus external guide sequence (EGS)-mediated RNase P cleavage.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cells)Activity measurement

    Very high shRNAi targeting in transient transfection was not maintained in stably transfected clones and was not efficiently transmitted through the mouse germline.

    In plain wordsIn cells and mice, strong gene knockdown in short-term tests was not kept in stable cell clones or passed on through the mouse germline.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseDurability of shRNAi knockdown in stable clones and mouse germline
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Very high targeting achieved with an shRNAi expressed from an RNA polymerase III promoter in transient transfection was not maintained in stably transfected clones and was not efficiently transmitted through the mouse germline.
    1 context sentence
    Summary · context
    Therefore, we have used the Tbeta4 gene to compare alternative strategies for RNA targeting, namely short hairpin (sh) RNAi versus external guide sequence (EGS)-mediated RNase P cleavage.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.